A phase II clinical trial (NCT03592641) is evaluating the efficacy and safety of savolitinib, a selective anti-MET tyrosine kinase inhibitor (TKI), in patients with MET-amplified metastatic colorectal cancer. This evidence concerns the gene MET and metastatic colorectal cancer.